PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
41.00%
Gross profit growth of 41.00% while AVXL is zero. Bruce Berkowitz would see if minimal improvements could expand further.
27.93%
EBIT growth above 1.5x AVXL's 6.49%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
27.93%
Operating income growth above 1.5x AVXL's 6.49%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
29.77%
Net income growth above 1.5x AVXL's 10.05%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
30.61%
EPS growth above 1.5x AVXL's 7.14%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
30.61%
Diluted EPS growth above 1.5x AVXL's 7.14%. David Dodd would see if there's a robust moat protecting these shareholder gains.
2.13%
Slight or no buybacks while AVXL is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
2.13%
Slight or no buyback while AVXL is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
32.67%
OCF growth 1.25-1.5x AVXL's 23.56%. Bruce Berkowitz would see if superior pricing or efficient operations explain the gap.
32.86%
FCF growth 1.25-1.5x AVXL's 23.56%. Bruce Berkowitz would see if capex decisions or cost controls create a cash flow advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
83.05%
Positive long-term OCF/share growth while AVXL is negative. John Neff would see a structural advantage in sustained cash generation.
75.83%
5Y OCF/share CAGR above 1.5x AVXL's 17.65%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
20.41%
3Y OCF/share CAGR at 75-90% of AVXL's 24.64%. Bill Ackman would press for improvements in margin or overhead to catch up.
95.17%
Net income/share CAGR above 1.5x AVXL's 60.12% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
79.59%
5Y net income/share CAGR above 1.5x AVXL's 0.07%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
2.82%
Positive short-term CAGR while AVXL is negative. John Neff would see a clear advantage in near-term profit trajectory.
170.99%
Below 50% of AVXL's 776.38%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
-42.91%
Negative 5Y equity/share growth while AVXL is at 294.99%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-60.55%
Negative 3Y equity/share growth while AVXL is at 319.69%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative near-term dividend growth while AVXL invests at 0.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.43%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-18.27%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-4.43%
We’re deleveraging while AVXL stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-31.86%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-15.50%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.